Universe Pharmaceuticals INC (NASDAQ:UPC) Short Interest Update

Universe Pharmaceuticals INC (NASDAQ:UPCGet Free Report) was the recipient of a large increase in short interest during the month of June. As of June 30th, there was short interest totaling 239,483 shares, an increase of 1,955.8% from the June 15th total of 11,649 shares. Currently, 99.8% of the company’s shares are sold short. Based on an average daily trading volume, of 7,749,497 shares, the days-to-cover ratio is presently 0.0 days.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings raised Universe Pharmaceuticals from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Monday, June 29th. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the stock currently has an average rating of “Sell”.

View Our Latest Analysis on UPC

Universe Pharmaceuticals Trading Down 1.3%

Shares of UPC traded down $0.07 during trading hours on Friday, reaching $5.27. 308,161 shares of the company traded hands, compared to its average volume of 4,370,532. The company’s fifty day moving average price is $3.69 and its two-hundred day moving average price is $3.49. Universe Pharmaceuticals has a 12 month low of $2.00 and a 12 month high of $17.96.

About Universe Pharmaceuticals

(Get Free Report)

Universe Pharmaceuticals, Inc is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics for ocular diseases. The company’s primary research efforts center on small-molecule compounds designed to address unmet needs in glaucoma, ocular hypertension and post-surgical ocular inflammation. By leveraging targeted enzyme inhibition and proprietary formulation technologies, Universe aims to bring forward topically administered medications that combine efficacy with an improved safety profile versus existing treatments.

The company’s lead candidate, UPC-1001, has been advanced into clinical trials for the treatment of open-angle glaucoma and ocular hypertension, where it seeks to lower intraocular pressure through a unique mechanism of action.

See Also

Receive News & Ratings for Universe Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Universe Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.